CPA
AQST icon

Capital Performance Advisors’s Aquestive Therapeutics AQST Stock Holding History

Capital Performance Advisors’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-119
Closed -$593 – 333
2024
Q3 		$593 Buy
+119
New +$463 ﹤0.01% 2171

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Capital Performance Advisors's AQST Position: Q4 2024 in Review

Capital Performance Advisors sold out of Aquestive Therapeutics (AQST) in Q4 2024, closing a stake of 119 shares — an estimated $593 sold.

Capital Performance Advisors first reported a position in AQST in Q3 2024 and held it in 1 quarter. The position peaked at $593 in Q3 2024. 114 funds tracked by Wall St. Rank hold AQST as of Q4 2024.

  • Capital Performance Advisors reported no remaining Aquestive Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 119 Aquestive Therapeutics shares in Q4 2024, an estimated $593.
  • Capital Performance Advisors first reported a position in Aquestive Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Aquestive Therapeutics position peaked at $593 in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.